Scientific Publications

Advancing dermatological science.

May 2024

JAAD

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

March 2024

EADV 2024

Once-Daily Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Patients With Diverse Skin Types: Pooled Subgroup Analysis From the Phase 3 INTEGUMENT-1 and -2 Trials

March 2024

AAD 2024

Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR trial

March 2024

AAD 2024

Roflumilast Cream 0.3% in Patients With Psoriasis: Improvement in Patient-Reported Outcomes and Pruritus From Two Pooled Phase 3 Trials (DERMIS-1/DERMIS-2)

March 2024

AAD 2024

Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Clinical Trials of Adults and Children With Atopic Dermatitis

March 2024

AAD 2024

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients 2 to 5 Years of Age with Mild to Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial

March 2024

AAD 2024

Roflumilast Foam 0.3% Once Daily in Patients With Seborrheic Dermatitis: Improvement in Patient-Reported Outcomes and Pruritus From a Phase 3 Trial (STRATUM)

October 2023

Br J Dermatol

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study

May 2023

JAMA Dermatology

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

March 2023

AAD 2023

Efficacy and Safety of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials

March 2023

AAD 2023

Patient and Healthcare Provider Perspectives on the Path to Diagnosis of Seborrheic Dermatitis: Results From a National Survey of Adults With Seborrheic Dermatitis in the United States

March 2023

AAD 2023

Patient and Healthcare Provider Perspective on the Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download